Ifrah Financial Services Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 28,288 shares of the biopharmaceutical company’s stock after acquiring an additional 2,793 shares during the period. Ifrah Financial Services Inc.’s holdings in Pfizer were worth $1,004,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in PFE. AXA raised its stake in Pfizer by 9.2% during the 4th quarter. AXA now owns 5,188,453 shares of the biopharmaceutical company’s stock valued at $187,926,000 after purchasing an additional 438,040 shares during the period. SG Americas Securities LLC raised its stake in Pfizer by 3,116.6% during the 4th quarter. SG Americas Securities LLC now owns 1,186,121 shares of the biopharmaceutical company’s stock valued at $42,961,000 after purchasing an additional 1,149,246 shares during the period. Oldfield Partners LLP raised its stake in Pfizer by 33.1% during the 4th quarter. Oldfield Partners LLP now owns 109,850 shares of the biopharmaceutical company’s stock valued at $3,979,000 after purchasing an additional 27,300 shares during the period. WealthTrust Fairport LLC raised its stake in Pfizer by 5.2% during the 3rd quarter. WealthTrust Fairport LLC now owns 64,333 shares of the biopharmaceutical company’s stock valued at $2,297,000 after purchasing an additional 3,188 shares during the period. Finally, Savant Capital LLC raised its stake in Pfizer by 4.4% during the 4th quarter. Savant Capital LLC now owns 54,941 shares of the biopharmaceutical company’s stock valued at $1,990,000 after purchasing an additional 2,300 shares during the period. Institutional investors own 69.44% of the company’s stock.
Pfizer stock opened at $36.38 on Wednesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27. The firm has a market cap of $217.34 billion, a price-to-earnings ratio of 13.73, a price-to-earnings-growth ratio of 1.81 and a beta of 0.91. Pfizer Inc. has a one year low of $32.32 and a one year high of $39.43.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.03. The firm had revenue of $12.91 billion for the quarter, compared to the consensus estimate of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.69 earnings per share. sell-side analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, June 1st. Shareholders of record on Friday, May 11th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.74%. The ex-dividend date of this dividend was Thursday, May 10th. Pfizer’s payout ratio is 51.32%.
In other Pfizer news, CEO Ian C. Read sold 132,312 shares of the stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total transaction of $4,764,555.12. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Laurie J. Olson sold 19,000 shares of the stock in a transaction on Wednesday, June 6th. The stock was sold at an average price of $36.45, for a total transaction of $692,550.00. Following the transaction, the executive vice president now directly owns 98,644 shares in the company, valued at $3,595,573.80. The disclosure for this sale can be found here. Insiders have sold 156,535 shares of company stock worth $5,647,222 over the last three months. Company insiders own 0.06% of the company’s stock.
PFE has been the topic of several recent analyst reports. Credit Suisse Group reissued a “neutral” rating and set a $39.00 target price on shares of Pfizer in a research note on Friday, May 18th. Barclays downgraded shares of Pfizer from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $41.00 to $38.00 in a research note on Thursday, April 5th. Morgan Stanley reaffirmed a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research note on Monday, June 11th. ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, April 6th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $40.27.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.